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Abstract
Dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD) are charac-
terized by the presence of α-synuclein-containing Lewy bodies and Lewy neurites.
However, both dementias also show variable degrees of Alzheimer’s disease (AD) pathol-
ogy (senile plaques and neurofibrillary tangles), particularly in areas of the cortex associ-
ated with higher cognitive functions. This study investigates the contribution of the
individual and combined pathologies in determining the rate of cognitive decline. Cortical
α-synuclein, phosphorylated tau (phosphotau) and Aβ plaque pathology in 34 PDD and 55
DLB patients was assessed semi-quantitatively in four regions of the neocortex. The decline
in cognition, assessed by Mini Mental State Examination, correlated positively with the
cortical α-synuclein load. Patients also had varying degrees of senile Aβ plaque and
phosphotau pathology. Regression analyses pointed to a combined pathology (Aβ plaque
plus phosphotau plus α-synuclein-positive features), particularly in the prefrontal cortex
(BA9) and temporal lobe neocortex with the superior and middle temporal gyrus (BA21,
22), being a major determining factor in the development of dementia. Thus, cognitive
decline in Lewy body dementias is not a consequence of α-synuclein-induced neuro-
degeneration alone but senile plaque and phosphorylated tau pathology also contribute to
the overall deficits.
INTRODUCTION
The pathological substrate of dementia and cognitive decline in
Lewy body dementias is an important issue for the development
of biomarkers to measure outcome and for intervention studies.
In both dementia with Lewy bodies (DLB) and Parkinson’s
disease dementia (PDD), the severity of dementia is often
considered to be a function of cortical Lewy body formation
(12) although senile plaques and neurofibrillary tangles, the
pathognomic features of Alzheimer’s disease (AD), are also
found in DLB and PDD (14, 21). There has been considerable
recent interest in this area with a number of studies focusing on
the overlap of Alzheimer and Lewy body pathologies, although
few reports have included cognitive or other clinical assessments
of severity. Two recent studies (11, 24), despite only including
patients with PDD and PD (and not DLB), are perhaps the most
informative, highlighting the possible importance of cortical Aβ
and phosphorylated tau (phosphotau) in the rate of decline into
dementia. Analyses in other studies, however, support the role of
α-synuclein in determining the decline in cognitive state in both
PDD and DLB (23, 43).
To address this issue, in our study, neuropathology (senile
plaques, phosphotau pathology and α-synuclein-positive Lewy
bodies and neurites) has been analyzed in groups of DLB and PDD
patients where we were able to assess this pathology with respect
to rate of cognitive decline determined by serial assessments over
the years of dementia (1). This novel approach, therefore, allows
the provision of significant support for the hypothesis that all three
cortical pathologies relate to the premortem rate of cognitive
decline to establish that all three pathologies play a role in the
development of dementia.
MATERIALS AND METHODS
Assessment of cases
All cases were selected based on clinicopathological consen-
sus diagnoses. Clinical classification of PDD was made when
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parkinsonism preceded dementia by more than a year (34); diagno-
sis of DLB was made when cognitive impairment or hallucinations
were present before or within 1 year of onset of parkinsonism. All
cases were prospectively assessed by experienced clinicians using
validated clinical rating instruments. AD cases were clinically
diagnosed on the basis of meeting the Consortium to Establish a
Registry for Alzheimer’s Disease (CERAD) criteria for a diagnosis
of probable or definite AD, DLB according to international consen-
sus criteria (34) and PDD according to Movement Disorders
Society criteria (16). Neuropathological assessment was performed
according to standardized neuropathological scoring/grading
systems, including neurofibrillary Braak staging (threads and
tangles), CERAD scores (neuritic plaques), Newcastle/McKeith
Criteria for Lewy body disease (Lewy bodies and neurites),
National Institute on Aging—Alzheimer’s Association guidelines
and phases of amyloid-β (Aβ) deposition (5, 34, 37, 45). Cognitive
impairment data were assessed annually and are presented as the
annual decline in Mini Mental State Examination (MMSE) scores
from the time of dementia diagnosis, usually over the 8–10 years
prior to death (MMSE decline).The demographics and clinical state
of the PDD, DLB and AD patients is shown in Table 1. Full details
of the patient cohorts are presented in Supplementary Table S1.
More details of the selection and clinical assessment procedures can
be seen elsewhere (1—Newcastle and Oxford cohorts).
Brain tissue
Tissue was provided (seven micron wax sections) by the University
Hospital Stavanger (27 cases), Newcastle University (21 cases)
and the Thomas Willis Oxford (17 cases) Brain Collections and the
London Neurodegenerative Diseases Brain Bank (65 cases), the
UK sites being part of the Brains for Dementia Research network.
In all cases, formalin fixation time was less than 3 months.
Samples from prefrontal cortex (BA9), temporal lobe neocortex
with the superior and middle temporal gyrus (BA21, 22), anterior
cingulate cortex (BA24) and inferior parietal lobe neocortex
(BA40) were studied. In total, 55 DLB patients (age 65–92), 34
PDD patients (age 68–89), 16 AD patients (age 72–103 years) and
25 aged controls (age 65–96) were included. All participants gave
informed consent for their tissue to be used in research and the
study had ethical approval (08/H1010/4). Control cases (from the
above brain banks) were neurologically normal, with only mild,
age-associated neuropathological changes and no history of psy-
chiatric disease. The pathological features in these latter subjects
were not of sufficient severity to change the classification of them
from being neurologically normal, aged controls.
Immunohistochemistry
Labeling of neuropathology was undertaken by standard protocols.
Briefly, sections were dewaxed and rehydrated through xylene and
descending concentrations of alcohol into water. For Aβ and
phosphotau, antigen retrieval was carried out by either immersion
in 98% formic acid for 6 h (for Αβ labeling) or microwaving for 10
minutes in citrate buffer pH 6.0 (phosphotau). For α-synuclein,
antigen retrieval was carried out by autoclaving for 10 minutes in
ethylenediaminetetraacetic acid buffer pH 8.0 followed by immer-
sion for 15 minutes in 98% formic acid. Endogenous peroxidases
were subsequently blocked by 0.3% hydrogen peroxide in Tris-
buffered saline (30 minutes). Primary antibodies were added (Αβ,
1:1000 Dako M0872, Dako Ltd., Ely, Cambs., UK; phosphotau,
AT8 1:4000 Thermo Scientific MN1020, Thermo Fisher Scientific,
Cramlington, Northumberland, UK; α-synuclein, NCL-SYN 1:30
Novacastra Laboratories, Newcastle upon Tyne, UK) and tissue
sections incubated 1 h at room temperature. Subsequent horse-
radish peroxidase (HRP) and diaminobenzidine color development
was performed using Menarini X-Cell plus polymer HRP detec-
tion kit (MP-XCPDAD-U100, Menarini Diagnostics, Winnersh-
Wokingham, Berks., UK).
Semi-quantitative pathology scoring
Senile plaques were assessed by Aβ labeling. Neurofibrillary
tangles, neuritic plaques, dystrophic neurites and neuropil threads
were detected and evaluated by a combination of phosphotau
immunohistochemistry (AT8 antibody) and silver impregnation
(Gallyas or modified Bielschowsky) (2). Assessment of α-
synuclein pathology included Lewy neurites and Lewy bodies. A
semi-quantitative assessment was preferred to a morphometric
approach in order to provide a means for considering summated
pathologies. Semi-quantitative assessments of senile Aβ plaques,
phosphotau and α-synuclein pathology were conducted blind to
clinical diagnosis, by experienced neuropathologists, using a
four-tiered scale of 0 (none), 1 (sparse), 2 (moderate) and 3
(severe/frequent) to score sections from each brain area, as
described previously (48). All cases were reviewed by a single
Table 1. Demographics and clinical data of patients included in the study.
n Age (years) Gender
M/F
PMD (h) Braak Years of
dementia
MMSE last MMSE decline
per year
PDD 34 79.9 ± 6.0 12/22 33.5 ± 15.6 0–5 4.1 ± 2.7 12.7 ± 8.0 2.0 ± 1.6
DLB 55 81.7 ± 6.5 39/16 41.3 ± 28.0 1–6 6.2 ± 3.1 14.1 ± 8.1 3.6 ± 3.6
PDD + DLB 89 80.2 ± 6.4 51/38 37.3 ± 24.2 0–6 5.3 ± 3.1 13.4 ± 8.0 2.9 ± 2.9
AD 16 88.1 ± 7.8 5/11 25.2 ± 21.6 4–6 10.1 ± 2.6 8.6 ± 7.6 3.8 ± 3.7
Control 25 79.7 ± 7.6 14/11 35.4 ± 22.3 0–2
“Braak” refers to NFT Braak stage. “MMSE last” is the score at the last interview before death. “MMSE decline” is the decline per year averaged
over the period of clinical observation and was usually 8–10 years. No MMSE data are available in the aged control group. Data are expressed as
mean ± standard deviation.
Abbreviations: AD = Alzheimer’s disease; DLB = dementia with Lewy bodies; MMSE = Mini Mental State Examination; PDD = Parkinson’s disease
dementia; PMD = post mortem delay.
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neuropathologist to confirm that there was no interobserver vari-
ability. After preliminary observations, it was reasoned that the low
AD group number and severe plaque and phosphotau pathology
would skew the overall statistical comparisons; the AD patients
were subsequently excluded from statistical analyses principally
aimed at exploring pathology and cognition in the Lewy body
diseases, although the pathology data are included in order to
provide a benchmark for the level of plaque and phosphotau occur-
rence in DLB, PDD and controls, compared with AD.
Immunoassays
Briefly, samples were treated with 8 × 5 M guanidine, 50 mM Tris-
HCl buffer at room temperature for 4 h, followed by dilution with
1:50 cold reaction buffer [50 mM Tris-HCl buffer, pH 7.5 with
addition of protease inhibitors (Roche Diagnostics, Burgess Hill,
West Sussex, UK) and 2 μg/mL pepstatin A (Sigma Aldrich,
Gillingham, Dorset, UK)]. Guanidine/Tris-HCl homogenates
were assayed in duplicate as recommended by the manufacturer
for the Aβ42 enzyme-linked immunosorbent assay (ELISA) kit
(#KHB3442), Aβ40 ELISA kit (#KHB3482), tau pS396 ELISA kit
(#KHB7031) and total tau ELISA kit (#KHB0042) (all InVitrogen,
Life Technologies, Paisley, Scotland).
Statistical analysis
Non-parametric bivariate correlations and regression analyses
(stepwise method in SPSS, IBM UK Ltd., Portsmouth, UK) were
used to determine relationships between variables. Correlations
were determined considering MMSE decline per year and regional
pathologies as variables. Preliminary analyses (not shown) consid-
ered the MMSE score at the last interview before death; the cor-
relations generated suggested that this factor was not as important
as MMSE decline as a dependent variable. Backward regression
analyses employed MMSE decline per year as the dependent vari-
able and the brain area pathologies as independent variables.
Where stated, groups were compared by Student’s t-test.
RESULTS
The semi-quantitative scores for frequency of senile Aβ plaques
(0–3), phosphotau (0–3) and α-synuclein pathology (0–3) in the
three disease states and healthy controls are shown in Figure 1. The
control cases showed varying frequencies of Αβ-positive senile
plaques in all four cortical regions studied, a scarcity of
neurofibrillary pathology and an absence of α-synuclein pathol-
ogy. Overall, PDD was characterized by α-synuclein inclusions
and senile Αβ-positive plaques in the four regions of cortex, with
a lesser incidence of neurofibrillary tangles (NFT’s). DLB
patients, however, exhibited marked plaque, phosphotau and
α-synuclein pathology throughout the cortical regions. The AD
patients, included for comparative purposes, showed severe plaque
and phosphotau pathology in prefrontal cortex (BA9), temporal
lobe neocortex with the superior and middle temporal gyrus
(BA21, 22), and inferior parietal lobe neocortex (BA40), some-
what less in anterior cingulate cortex (BA24) and a fairly sparse
occurrence of Lewy bodies (Figure 1 and Table 2).
The possibility of MMSE decline being a product of a summa-
tion of the various pathologies was considered in the individual
patient groups. The semi-quantitative scores (0–3) for plaques,
phosphotau and α-synuclein pathology were summed to give an
overall pathology measure for each region (0–9). In these groups,
the pathology summation score (PSS) correlated with the MMSE
decline for the PDD and PDD + DLB patients in BA9, BA21 and
BA40 (Table 3A). Only in BA21 was there a correlation between
PSS and MMSE decline in the DLB group. The major contributor
to these correlations would appear to be the α-synuclein compo-
nent as a number of significant correlations were also observed
between α-synuclein scores and MMSE decline in PDD and
PDD + DLB groups (and BA21 in the DLB patients) (Table 3A). It
was noticeable, however, that the R values for PSS vs. MMSE
decline in the PDD group was greater than that for α-synuclein
alone vs. MMSE decline in all four brain areas studied, suggesting
a possible summation effect. There were, additionally, significant
correlations between cortical plaque and MMSE decline in the
PDD group and cortical phosphotau and MMSE decline in the
PDD + DLB combined group (Table 3A), although there were no
differences in rate of MMSE decline between the NFT Braak
stages (data not shown). There were no significant associations
between cognitive decline and age or gender (data not shown).
Guanidine HCl extracts of BA9 and BA21 tissue were analyzed
by ELISA for Αβ40, Αβ42, total tau and phosphorylated serine
396 tau. Both BA9 and BA21 Αβ40 and Αβ42 concentrations
correlated significantly with the respective plaque scores for the
two areas (P < 0.001 for all comparisons) and BA9 and BA21
phosphorylated serine 396 tau (but not total tau) correlated with
NFT scores (P < 0.0001) (data not shown). MMSE decline for the
PDD + DLB and PDD alone groups was found to correlate sig-
nificantly with BA9 Αβ40 and Αβ42 concentrations (Table 3B).
BA9 Αβ40 and Αβ42 to Αβ40 ratio also correlated with MMSE
decline in these patient groups as did BA21 Αβ42. In the DLB
patients, only Αβ42 demonstrated a significant correlation with
MMSE decline. There were no significant correlations with
MMSE decline when total tau or phosphorylated serine 396 tau
data were assessed (data not shown).
A series of backward stepwise regression analyses were con-
ducted to assess the major pathological variable(s) with respect to
MMSE decline. For the PDD + DLB and DLB only groups, this
variable was BA21 α-synuclein pathology while for the PDD
group it was BA9 α-synuclein (Table 4). Based on the observed
significant correlations between MMSE decline and both PSS and
α-synuclein in BA9, BA21 and BA40 (Table 3A), a similar back-
ward stepwise regression analysis was conducted. Considering the
individual pathologies, BA21 α-synuclein was the major signifi-
cant variable in the DLB and grouped PDD + DLB patients and
BA9 α-synuclein in PDD patients. When a regression analysis of
α-synuclein and PSS was undertaken, BA21 PSS was the greater
determinant in DLB and PDD + DLB (Table 4).
DISCUSSION
This study investigates the role of individual and combined
pathologies in the rate of cognitive decline in clinically and patho-
logically defined Lewy body dementia cases. The data indicate that
although there were significant correlations between Lewy body
incidence and cognitive decline across a number of cortical
regions, a pathological assessment, where scores for senile Aβ
Howlett et al Cognitive Decline in Lewy Body Dementias
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plaque, phosphotau and α-synuclein loads were combined, pro-
vided an excellent correlate in both PDD and DLB patients.
The rate of decline in cognition is a more appropriate clinical
measure than a single determination at the last interview before
death (1). Our analyses, therefore, link the development of demen-
tia in the years before death with the incidence of the different
neuropathologies. Agreement on the involvement of AD-type
pathologies in the Lewy body dementias is not universal and may
reflect the differing means of assessing dementia. In a group of
PDD patients, cortical plaque (but not α-synuclein) and MMSE
score at the last interview before death was predictive of a shorter
time to dementia and a combination of the pathologies was found
to be a greater predictor of dementia than the individual loads (11).
Cortical plaque was also associated with a shorter survival time
Figure 1. Frequency of pathology scores in (A) control, (B) Parkinson’s
disease dementia, (C) dementia with Lewy bodies and (D) Alzheimer’s
disease. The frequency of each pathology score, by brain region, was
calculated as described in “Materials and Methods” section. The left-
hand y-axis represents the percentage of cases with a particular score.
BA9, BA21, BA24 and BA40 refer to the Brodmann areas, as defined in
Materials and Methods section. “α-Syn” is α-synuclein labeling of Lewy
bodies and neurites; “tangles” refer to phosphorylated tau labeling of
neurofibrillary tangle and neurites; “plaques” is labeling of senile
plaques with an antibody to Aβ.
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in PDD patients (28). A study of over 100 PDD patients reported
that Lewy body score, Braak neurofibrillary tangles and plaque
densities were greater than in a group of non-demented PD
patients and the plaque and tau loads correlated with the state of
dementia (23). The degree of dementia in a large DLB cohort
(>150 patients), determined longitudinally by a battery of cogni-
tive function tests, was found to be associated with Lewy body
pathology and was independent of amyloid and tau pathology (43),
while in a small (22 patients) group of DLB patients cortical and
subcortical Aβ pathology correlated with the incidence of Lewy
bodies, although no clinical measures were described (10).
Classically, AD patients have been defined by the presence of
senile plaques and NFTs, and Lewy body dementias by
α-synuclein-positive intracellular inclusions and neurites. Increas-
ingly, however, data point to a “graying” of the pathological
boundaries between these disorders and the occurrence of multiple
neuropathologies, the “multimorbidity” theory (3). Equally, other
studies have suggested that AD pathology in particular plays a role
in cognitive decline in Lewy body dementias (11, 20, 23, 36). In
agreement with previous data (28), the present study illustrates
that it is not uncommon to observe α-synuclein, senile Αβ plaque
and phosphotau pathology in all three dementias. Studies have
previously attempted to relate the cognitive decline in PDD and
DLB to the presence of AD pathology with conflicting results, the
latter probably arising as a consequence of issues relating to diag-
nosis and sample population (29). We attempted a relatively crude
assessment of the total pathology in any brain region studied by
simply adding together the individual pathology scores for
α-synuclein, Αβ-positive plaques and phosphotau to give a PSS.
The analysis showed that despite the importance of α-synuclein
pathology, particularly in BA9 and BA21, the combined pathology
score for plaques, phosphotau and α-synuclein-positive features
(the PSS) in these areas was a major variable determining the
severity of the cognitive deficit, as defined by MMSE decline, in
the individual PDD and DLB patient groups. Although MMSE
scoring was developed primarily for assessing cognitive decline in
AD, our data do highlight its usefulness in other dementias.
The implication of the involvement of BA9 (part of the
dorsolateral prefrontal cortex) is supportive of Lewy body demen-
tia patients showing deficits in executive function (33), which
is thought to be largely subserved through the dorsolateral
prefrontal cortex (8). Similarly, the temporal cortex (which
includes BA21) is believed to be involved in memory and
visuospatial recognition, key features in PDD and DLB. Thus, the
occurrence of BA9 and BA21 Lewy pathology can be associated
with the deficiencies in neurological functions characteristic of
PDD and DLB patients. Neurofibrillary tangle density and
α-synuclein load have also been reported to be instrumental in the
cognitive decline over 13 years in a cohort of 354 Catholic nuns,
priests and brothers (49), suggesting a multipathology role in cog-
nitive decline in old age.
The two forms of dementia associated with Lewy pathology,
DLB and PDD are usually distinguished and defined clinically by
the temporal relationship between the respective onsets of demen-
tia and motor defects (11), and commonality exists for Lewy body
presence and distribution associated with the two dementias with
little difference in neuropathology (13). An association of plaque
pathology with the rate of cognitive decline in DLB patients and a
greater plaque burden in DLB than PDD has been reported (18,
42). Despite also observing a greater plaque (and tangle) load in
the present group of DLB patients, there was no association
between MMSE decline and plaque or phosphotau pathology.
Only by grouping all Lewy body patients together (PDD + DLB)
and ignoring the clinical division between PDD and DLB patients
was there a correlation between the rate of MMSE decline and the
incidence of phosphotau pathology (BA9, BA21 and BA40),
Table 2. Individual pathology scores for
senile plaques, neurofibrillary tangles and
α-synuclein inclusions in four cortical areas in
PDD, DLB, AD and control cases.
Plaque BA9 Plaque BA21 Plaque BA24 Plaque BA40
Control 0.35 ± 0.65 0.57 ± 0.84 0.29 ± 0.78 0.39 ± 0.78
PDD 1.39 ± 1.10 0.74 ± 0.88 0.97 ± 0.83 1.23 ± 0.91
DLB 1.68 ± 1.07 1.73 ± 1.04 1.28 ± 1.07 1.47 ± 1.09
AD 2.81 ± 0.54 2.81 ± 0.54 1.47 ± 1.06 2.63 ± 0.72
Tangles BA9 Tangles BA21 Tangles BA24 Tangles BA40
Control 0.17 ± 0.39 0.30 ± 0.70 0.10 ± 0.30 0.04 ± 0.21
PDD 0.53 ± 0.61 0.44 ± 0.59 0.53 ± 0.63 0.48 ± 0.72
DLB 0.93 ± 0.84 1.31 ± 0.98 1.23 ± 1.02 0.98 ± 0.89
AD 2.56 ± 0.51 2.81 ± 0.54 1.44 ± 1.26 2.81 ± 0.40
α-Synuclein BA9 α-Synuclein BA21 α-Synuclein BA24 α-Synuclein BA40
Control 0.00 0.00 0.00 0.00
PDD 0.79 ± 1.06 0.94 ± 0.81 1.85 ± 1.04 0.59 ± 1.77
DLB 1.62 ± 1.05 1.75 ± 1.09 2.28 ± 0.92 1.39 ± 0.98
AD 0.13 ± 0.34 0.20 ± 0.41 0.31 ± 0.70 0.13 ± 0.34
Areas studied were BA9 (prefrontal cortex), BA21, 22 (temporal lobe neocortex with the superior
and middle temporal gyrus), BA24 (anterior cingulate cortex) and BA40 (inferior parietal lobe
neocortex). Plaque, tangle and α-synuclein pathology was assessed on a semi-quantitative scale as
described in Materials and Methods section. Data are means ± standard deviations from the
scoring of patients shown in Table 1.
Abbreviations: AD = Alzheimer’s disease; DLB = dementia with Lewy bodies; PDD = Parkinson’s
disease dementia.
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although these correlations were never as strong as between PSS
and rate of MMSE decline.
Employing Lewy body dementia groups with >30 patients, we
observed that the decline in cognition in the years before death in
the DLB patients correlated with cortical Lewy pathology (defined
by α-synuclein immunohistochemistry) in BA9, BA21 and BA40;
in the PDD patients a correlation with only BA9 α-synuclein
immunohistochemistry was observed. The role of cortical
α-synuclein and plaque pathologies in cognitive decline in PDD is
supported by data showing that the duration of parkinsonian symp-
toms prior to dementia is associated with less severe cortical
α-synuclein and lower plaque scores (4) and cerebral plaque depo-
sition (assessed by PiB binding) was lower in PD patients at risk of
dementia than in cognitively normal control subjects (40).
However, the presence of fibrillar Aβ, as detected by PET scan-
ning, has been described in PD patients with early dementia (6, 7).
In other words, it is during phases of cognitive decline that these
pathologies play a major role.
The relevance of plaque Αβ to neurodegeneration and cognitive
decline has been widely debated (13, 15, 39), with the suggestion
that soluble oligomeric forms of the protein play a greater role in
neuronal loss (44, 46, 47). In the present study, guanidine extract-
able Αβ40 and Αβ42 was found to correlate with plaque Αβ, and
in BA9, these Αβ species correlated with MMSE decline in both
the PDD and combined PDD + DLB patient groups. Although the
soluble oligomeric component of these extracts may play a role in
cognitive decline, the fact that the proportion of extractable (SDS,
guanidine hydrochloride, formic acid) to freely soluble Αβ is
extremely high (27, 41) suggests that the less soluble forms requir-
ing dissolution in guanidine hydrochloride are likely to be of
significance in the dementia process.
There is clearly a mixed morbidity state in these dementias
although the etiology is not clear. In both familial AD (FAD) and
Down syndrome (DS), classical AD pathology can be accompa-
nied by the presence of Lewy bodies and Lewy neurites (30, 31).
As well as forming the cornerstone of the “amyloid hypothesis” of
AD (22) in demonstrating that mutations in the APP gene or its
overexpression, directly or indirectly, both drive the formation of
NFTs, these studies in FAD and DS patients also point to a link
between amyloidogenesis and α-synuclein aggregation (35). Pro-
teins that are susceptible to mis-folding are also likely to promote
the aggregation of each other. For example, Αβ and α-synuclein
are able to act as seeds and affect aggregation of each other (32)
and tau and α-synuclein can interact and promote synergistic
fibrillization (17, 19). The biophysical features of AD pathology
(oligomeric/fibrillar Aβ and aggregated phosphotau) may act syn-
ergistically with α-synuclein to promote the aggregation and
spread of α-synuclein pathology (24). The seminal seeds of
dementia, therefore, while providing the definition of the disease
as AD or PDD/DLB, may be sufficient to facilitate the develop-
ment of the alternate pathologies that we and others have observed.
Certainly in a transgenic mouse model of AD, the introduction of
a human mutant α-synuclein transgene promoted both the Αβ and
tau pathology and also accelerated the cognitive decline, pointing
to a synergistic effect (9).
Table 3. Correlations between MMSE decline and pathology scores in
PDD and DLB patients in BA9 (prefrontal cortex), BA21, 22 (temporal
lobe neocortex with the superior and middle temporal gyrus), BA24
(anterior cingulate cortex) and BA40 (inferior parietal lobe neocortex).
(A) n PSS α-Synuclein Plaques Tangles
BA9 PDD + DLB 65–68 0.343 0.45 0.053 0.264
PDD 30–32 0.509 0.501 0.303 0.291
DLB 35–37 0.176 0.333 −0.139 0.183
BA21 PDD + DLB 65–69 0.406 0.467 0.231 0.291
PDD 28–32 0.358 0.156 0.359 0.302
DLB 36–37 0.423 0.577 0.127 0.217
BA24 PDD + DLB 64–68 0.227 0.315 0.142 0.139
PDD 32 0.255 0.109 0.255 0.268
DLB 32–36 0.132 0.258 0.129 0.036
BA40 PDD + DLB 65–69 0.389 0.475 0.067 0.283
PDD 29–32 0.441 0.309 0.370 0.186
DLB 36–37 0.273 0.474 −0.105 0.272
(B) n Αβ42 Αβ40 Ratio Aβ42:Aβ40
BA9 PDD + DLB 69 0.385 0.314 0.340
PDD 32 0.407 0.345 0.45
DLB 37 0.373 0.21 0.24
BA21 PDD + DLB 68 0.409 0.088 0.240
PDD 31 0.450 0.126 0.290
DLB 37 0.307 0.099 0.09
(A) Correlation (Rs) of pathology summary scores and individual pathol-
ogy scores with MMSE decline per year. PSS is the summation of
α-synuclein, plaque and tangle scores.
(B) Correlation (Rs) of Aβ40 and Aβ42 enzyme-linked immunosorbent
assay data with MMSE decline per year.
Values are Rs and those indicated in large bold italics indicate statis-
tically significant correlations (P < 0.05) between that variable and
MMSE decline.
Abbreviations: DLB = dementia with Lewy bodies; MMSE = Mini
Mental State Examination; PDD = Parkinson’s disease dementia;
PSS = pathology summation score.
Table 4. Regression analysis of α-synuclein, Aβ and phosphorylated tau
pathology in BA9, BA21, BA24 and BA40 in PDD and DLB patient
groups.
(A) All pathologies
Beta t Sig
PDD + DLB BA21 α-synuclein 0.417 3.381 0.001
PDD BA9 α-synuclein 0.372 2.043 0.053
DLB BA21 α-synuclein 0.603 3.929 0.001
(B) PSS and α-synuclein
Beta t Sig
PDD + DLB BA21 PSS 0.767 4.565 <0.0001
PDD BA9 PSS 0.566 3.434 0.002
DLB BA21 PSS 0.937 4.575 <0.0001
BA9 PSS −0.586 −2.861 0.008
(A) All three individual pathologies or (B) α-synuclein and PSS only were
analyzed in a backward stepwise regression model in BA9 (prefrontal
cortex), BA21, 22 (temporal lobe neocortex with the superior and middle
temporal gyrus), BA24 (anterior cingulate cortex) and BA40 (inferior
parietal lobe neocortex).
Abbreviations: DLB = dementia with Lewy bodies; PDD = Parkinson’s
disease dementia; PSS = pathology summation score.
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Although we studied the main neurodegenerative pathologies in
areas of the neocortex associated with higher cognitive functions,
a limitation of the study is that non-cortical brain regions with
dementia-linked pathology, such as the striatum (26) or thalamus
(25), were not included in this study. Furthermore, other poten-
tially relevant pathologies were not assessed, including vascular
pathology and TDP-43. Such features may be of relevance
although assessment criteria for vascular pathologies await stand-
ardization (2) and TDP-43 pathology is less frequent in pure
synucleinopathies than in diseases where tauopathy is the major
pathology (38). A strength of the present study is the prospective
design of the cohorts that allowed the calculation of the annual rate
of cognitive decline prior to death. This study, while not providing
unequivocal evidence that the dementia observed in Lewy body
diseases is a function of a multipathological insult by senile Αβ
plaque, phosphotau and α-synuclein, does point to the multiple
pathologies as playing a role in cognitive decline in these diseases,
findings that may have important implications in terms of clinical
practice and research.
Undoubtedly, the presence of α-synuclein-positive pathology is
a major correlate of cognitive decline in PDD and DLB patients.
These patients, however, develop variable levels of all three
pathologies and, in many cases, the summated deposition of these
proteins, as assessed by semi-quantitative scoring, correlated with
the decline in MMSE score. This relationship was the most striking
in BA9 and BA21, areas of major significance in AD but which
also appear to be determinants of cognitive decline in PDD and
DLB. Thus, using a rather simple and easily reproducible means of
assessment based on standard and routinely applied neuropath-
ological criteria, semi-quantitative scoring has provided evidence
that dementia in PDD and DLB is governed by multiple pathologi-
cal features in addition to their characteristic Lewy bodies.
CONCLUSIONS
Pathological assessment of Lewy body dementia and AD patient
groups demonstrated Αβ-positive senile plaques plus phosphotau-
and α-synuclein-positive pathologies. The presence of any of the
pathologies could not be considered a defining feature of any
particular dementia as evidence for each was observed across the
entire patient group. Obviously, attempting to correlate end-stage
pathology to cognitive decline in the latter years of life of any
dementia patient, as in the present study, may be open to criticism.
Nevertheless, summated pathology scores, particularly in areas
BA9 and BA21 in the PDD and DLB patients, demonstrated a
significant relationship with the decline in MMSE scores averaged
over the years before death, supporting the view that the summated
score was a better predictor of decline.
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